NAV

Solithromycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Solithromycin
DrugBank Accession Number
DB09308
Background

Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Similar Structures
Weight
Average: 845.0088
Monoisotopic: 844.474620535
Chemical Formula
C43H65FN6O10
Synonyms
  • Solithromycin
External IDs
  • CEM 101
  • CEM-101
  • OP 1068
  • OP-1068

Pharmacology

Indication

Investigated for the treatment of community-acquired pneumonia (CAP).

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Solithromycin.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Solithromycin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Solithromycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Solithromycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Solithromycin.
AlectinibThe metabolism of Alectinib can be decreased when combined with Solithromycin.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Solithromycin.
AlfuzosinThe metabolism of Alfuzosin can be decreased when combined with Solithromycin.
AlpelisibThe metabolism of Alpelisib can be decreased when combined with Solithromycin.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Solithromycin.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

ATC Codes
J01FA16 — Solithromycin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Phenyl-1,2,3-triazoles / Aniline and substituted anilines / Oxazolidinones / Oxanes / Alpha-haloketones / Carbamate esters / Heteroaromatic compounds / 1,2-aminoalcohols / Trialkylamines / Secondary alcohols
show 15 more
Substituents
1,2,3-triazole / 1,2-aminoalcohol / Acetal / Alcohol / Alkyl fluoride / Alkyl halide / Alpha-haloketone / Amine / Amino acid or derivatives / Aminoglycoside core
show 37 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
9U1ETH79CK
CAS number
760981-83-7
InChI Key
IXXFZUPTQVDPPK-ZAWHAJPISA-N
InChI
InChI=1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
IUPAC Name
(3aS,4R,7S,9R,10R,11R,13R,15R,15aR)-1-{4-[4-(3-aminophenyl)-1H-1,2,3-triazol-1-yl]butyl}-10-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-4-ethyl-7-fluoro-11-methoxy-3a,7,9,11,13,15-hexamethyl-tetradecahydro-1H-oxacyclotetradeca[4,3-d][1,3]oxazole-2,6,8,14-tetrone
SMILES
[H][C@]12N(CCCCN3C=C(N=N3)C3=CC(N)=CC=C3)C(=O)O[C@]1(C)[C@@]([H])(CC)OC(=O)[C@@](C)(F)C(=O)[C@]([H])(C)[C@@]([H])(O[C@]1([H])O[C@]([H])(C)C[C@]([H])(N(C)C)[C@@]1([H])O)[C@@](C)(C[C@@]([H])(C)C(=O)[C@]2([H])C)OC

References

General References
  1. Reinert RR: Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother. 2004 Jun;53(6):918-27. Epub 2004 Apr 29. [Article]
  2. Menache D: Replacement therapy in patients with hereditary antithrombin III deficiency. Semin Hematol. 1991 Jan;28(1):31-8. [Article]
  3. Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN: Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agents. 2010 Jun;35(6):537-43. doi: 10.1016/j.ijantimicag.2010.01.026. Epub 2010 Mar 7. [Article]
  4. McGhee P, Clark C, Kosowska-Shick KM, Nagai K, Dewasse B, Beachel L, Appelbaum PC: In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother. 2010 Jan;54(1):230-8. doi: 10.1128/AAC.01123-09. Epub 2009 Nov 2. [Article]
  5. Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN: CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis. 2010 Apr;66(4):393-401. doi: 10.1016/j.diagmicrobio.2009.10.013. [Article]
  6. Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M: Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Int J Antimicrob Agents. 2011 Jan;37(1):39-45. doi: 10.1016/j.ijantimicag.2010.08.021. [Article]
  7. Llano-Sotelo B, Dunkle J, Klepacki D, Zhang W, Fernandes P, Cate JH, Mankin AS: Binding and action of CEM-101, a new fluoroketolide antibiotic that inhibits protein synthesis. Antimicrob Agents Chemother. 2010 Dec;54(12):4961-70. doi: 10.1128/AAC.00860-10. Epub 2010 Sep 20. [Article]
PubChem Compound
25242512
PubChem Substance
310265196
ChemSpider
25056854
ChEMBL
CHEMBL1232510
ZINC
ZINC000095627834
PDBe Ligand
EM1
Wikipedia
Solithromycin
PDB Entries
4www

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)2
3CompletedTreatmentUncomplicated Urogenital Gonorrhea1
2CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
2CompletedTreatmentNon Alcoholic Steato Hepatitis1
2CompletedTreatmentUncomplicated Urogenital Gonorrhea1
2TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2, 3TerminatedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
1CompletedTreatmentBacterial Infections2
1CompletedTreatmentGonorrhoea1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0167 mg/mLALOGPS
logP4.22ALOGPS
logP5.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)12.8ChemAxon
pKa (Strongest Basic)7.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area197.87 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity230.73 m3·mol-1ChemAxon
Polarizability90.81 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created on November 12, 2015 16:46 / Updated on February 21, 2021 18:52